Autolus Therapeutics (AUTL) Net Income towards Common Stockholders (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$90.3 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 227.22% year-over-year to -$90.3 million; the trailing twelve-month figure through Dec 2025 stood at -$287.5 million (down 30.3% YoY), and the FY2025 full-year result was -$287.5 million, down 30.3% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$90.3 million, down from -$79.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$6.8 million in Q4 2021 and bottomed at -$34.0 billion in Q3 2021.
• The 5-year median for Net Income towards Common Stockholders is -$45.7 million (2023), against an average of -$1.7 billion.
• The widest annual swing landed in 2021, when Net Income towards Common Stockholders slumped 90992.05%; it then soared 99.87% in 2022.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$6.8 million in 2021, then tumbled by 298.16% to -$27.0 million in 2022, then slumped by 186.04% to -$77.2 million in 2023, then surged by 64.23% to -$27.6 million in 2024, then tumbled by 227.22% to -$90.3 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$90.3 million (Q4 2025), -$79.1 million (Q3 2025), and -$47.9 million (Q2 2025), per Business Quant data.

Peer Comparison